semaglutide blindness risk or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes Tirzepatide hits two receptors SAVE $13.5 Choose your Bundle::1 Bottle/1 Month Supply

semaglutide blindness risk or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes Tirzepatide hits two receptors SAVE $13.5 Choose your Bundle::1 Bottle/1 Month Supply

Tirzepatide hits two receptors — GIP and GLP-1. Semaglutide hits one. And that difference in mechanism is a big part of why the clinical outcomes look so different. GLP-1 slows gastric emptying

Tirzepatide versus dulaglutide as add-on therapy to SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3)

SAVE $13.5

Choose your Bundle::1 Bottle/1 Month Supply

The boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies — whether that translates to human medullary thyroid carcinoma risk has not been established, but the contraindication for personal/family history of MTC or MEN 2 is firm